A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban

Asleson, Louise; Zalabani, Mohammed; Selim, Mohammad

doi:10.7759/cureus.29491

Cited by 3 publications

(3 citation statements)

References 8 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 has also been associated with some cases of RVT, which is attributed to the ability of the virus to cause direct harm to the endothelium and trigger an overactive inflammatory response [ 1 , 2 ]. There have been documented case reports highlighting the occurrence of RVT in patients diagnosed with COVID-19 [ 4 , 5 ].…”

Section: Discussionmentioning

confidence: 99%

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report

Kakhktsyan,

Mousa,

Arshad

et al. 2023

Cureus

View full text Add to dashboard Cite

Renal vein thrombosis (RVT) is a rare condition characterized by the formation of a blood clot in one or both of the renal veins. Bilateral involvement is more common, but when the condition affects only one side, it usually occurs on the left due to more extensive venous vasculature compared to the right side. RVT can be caused by various factors such as trauma, dehydration, malignancy, and a hypercoagulable state. Acute RVT is typically more severe than chronic, and it can cause symptoms such as renal infarction, acute kidney injury, renal failure, severe flank pain, and hematuria. Some cases of RVT have also been linked to coronavirus disease 2019 (COVID-19), which is widely recognized to induce a hypercoagulable state. The standard treatment for RVT is warfarin but in this case report, we describe a COVID-19 patient with RVT whose thrombus was successfully treated with direct-acting oral anticoagulant (DOAC) apixaban for six months.

show abstract

Section: Discussionmentioning

confidence: 99%

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report

Kakhktsyan,

Mousa,

Arshad

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…In concordance with other studies, our case shows that RVT may be a consequence of COVID-19 infection or even a feature of long COVID. Other types of DOACs, such as Rivaroxaban, have shown positive results in treating RVT in single case studies ( 16 , 24 ). To the best of our knowledge, our study is the first to have used Apixaban as a treatment for a rare presentation of RVT in the renal arcuate veins.…”

Section: Discussionmentioning

confidence: 99%

“…Apixaban has been formerly shown as a reliable drug in treating venous thromboembolism. A randomized clinical trial of 5395 participants concluded that Apixaban therapy did not show inferior results compared to conventional therapy in venous thromboembolism patients (23). One of the few studies regarding DOACs treatment in the setting of VTE in atypical locations demonstrated that there were no statistically significant differences in VTE recurrence and hemorrhage risk between those treated with DOACs such as Rivaroxaban/Apixaban and those conventionally treated with low molecular weight Heparins such as Enoxaparin (14).…”

Section: Discussionmentioning

confidence: 99%

Case report: A case of renal arcuate vein thrombosis successfully treated with direct oral anticoagulants

et al. 2023

View full text Add to dashboard Cite

A rare case of a 35 years old woman presented with renal arcuate vein thrombosis (RAVT) and acute kidney injury (AKI) following upper respiratory tract symptoms and toxic substance ingestion. Histopathological evaluation of the patient's kidney tissue indicated a rare venous thrombosis in the renal arcuate veins. Anticoagulation with Apixaban, a direct oral anticoagulant (DOAC), was commenced, and the patient's symptoms resolved during the hospital stay. Hitherto, a limited number of studies have shown the concurrent presentation of RAVT and overt AKI in patients following ingestion of nephrotoxic agents. Further studies are necessary to elucidate the etiology, clinical presentation, and treatment of RAVT. We suggest that Apixaban be studied as a suitable alternative to conventionally used anti-coagulants such as Warfarin in patients who lack access to optimal health care facilities.

show abstract

Acute Renal Vein Thrombosis Following COVID-19 in a Lupus Patient: A Case Report and Review of the Literature

Petrou

Sardeli

Vlachoyiannopoulos

et al. 2023

Life

View full text Add to dashboard Cite

Purpose: The association between COVID-19 and hypercoagulability is well established. This is a case of a patient with systemic lupus erythematosus (SLE) who developed unilateral renal vein thrombosis following COVID-19, the third case described in the international literature so far. Methods: Clinical, laboratory characteristics and outcomes of the patient were described in detail. Literature review was performed on MEDLINE database via Pubmed. Search items included COVID-19, renal infarction, and renal thrombosis. A total of fifty-three cases were located. Of these, only two patients had renal vein thrombosis but none of them carried a diagnosis of SLE. However, six cases have been published so far involving SLE patients in whom thromboembolic events developed following COVID-19, but none of them experienced renal vein thrombosis. Conclusion: The present case adds a new piece to the emerging puzzle of COVID-19 associated hypercoagulability, especially among patients with autoimmune diseases.

show abstract

A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban

Cited by 3 publications

References 8 publications

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report

Case report: A case of renal arcuate vein thrombosis successfully treated with direct oral anticoagulants

Acute Renal Vein Thrombosis Following COVID-19 in a Lupus Patient: A Case Report and Review of the Literature

Contact Info

Product

Resources

About